In addition, cancer cells expressing a myelodysplastic syndrome-associated splicing factor mutation (SRSF2<sup>P95H</sup>) are more sensitive to one of these compounds than those expressing the wild-type version of the protein. This evidence concerns the gene SLU7 and myelodysplastic syndrome.